260 related articles for article (PubMed ID: 34207840)
1. Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins.
Rimpelová S; Kolář M; Strnad H; Ruml T; Vítek L; Gbelcová H
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207840
[TBL] [Abstract][Full Text] [Related]
2. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
[TBL] [Abstract][Full Text] [Related]
3. Variability in statin-induced changes in gene expression profiles of pancreatic cancer.
Gbelcová H; Rimpelová S; Ruml T; Fenclová M; Kosek V; Hajšlová J; Strnad H; Kolář M; Vítek L
Sci Rep; 2017 Mar; 7():44219. PubMed ID: 28276528
[TBL] [Abstract][Full Text] [Related]
4. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells.
Vanova K; Boukalova S; Gbelcova H; Muchova L; Neuzil J; Gurlich R; Ruml T; Vitek L
BMC Cancer; 2016 May; 16():309. PubMed ID: 27175805
[TBL] [Abstract][Full Text] [Related]
5. Differences in antitumor effects of various statins on human pancreatic cancer.
Gbelcová H; Lenícek M; Zelenka J; Knejzlík Z; Dvoráková G; Zadinová M; Poucková P; Kudla M; Balaz P; Ruml T; Vítek L
Int J Cancer; 2008 Mar; 122(6):1214-21. PubMed ID: 18027870
[TBL] [Abstract][Full Text] [Related]
6. Statins inhibit blastocyst formation by preventing geranylgeranylation.
Alarcon VB; Marikawa Y
Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer.
Chen C; Wu H; Kong D; Xu Y; Zhang Z; Chen F; Zou L; Li Z; Shui J; Luo H; Liu SH; Yu J; Wang K; Brunicardi FC
Oncol Rep; 2020 Dec; 44(6):2569-2580. PubMed ID: 33125137
[TBL] [Abstract][Full Text] [Related]
9. The effect of simvastatin on lipid droplets accumulation in human embryonic kidney cells and pancreatic cancer cells.
Gbelcová H; Svéda M; Laubertová L; Varga I; Vítek L; Kolář M; Strnad H; Zelenka J; Böhmer D; Ruml T
Lipids Health Dis; 2013 Aug; 12():126. PubMed ID: 23961716
[TBL] [Abstract][Full Text] [Related]
10. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
11. Statins decrease the expression of c-Myc protein in cancer cell lines.
Rao PS; Rao US
Mol Cell Biochem; 2021 Feb; 476(2):743-755. PubMed ID: 33070276
[TBL] [Abstract][Full Text] [Related]
12. Influence of HMG-CoA reductase inhibitors on leptin-induced endothelial cell proliferation, migration, and capillary-like tube formation.
Burgazli KM; Stein NI; Mericliler M; Parahuleva M; Erdogan A
Postgrad Med; 2014 May; 126(3):231-8. PubMed ID: 24918807
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
Karlic H; Thaler R; Gerner C; Grunt T; Proestling K; Haider F; Varga F
Cancer Genet; 2015 May; 208(5):241-52. PubMed ID: 25978957
[TBL] [Abstract][Full Text] [Related]
14. [The anticancer properties of statins].
Sławińska A; Kandefer-Szerszeń M
Postepy Hig Med Dosw (Online); 2008 Aug; 62():393-404. PubMed ID: 18688209
[TBL] [Abstract][Full Text] [Related]
15. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
[TBL] [Abstract][Full Text] [Related]
16. Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3.
Li Y; Müller AL; Ngo MA; Sran K; Bellan D; Arora RC; Kirshenbaum LA; Freed DH
J Cardiovasc Transl Res; 2015 Mar; 8(2):96-105. PubMed ID: 25547946
[TBL] [Abstract][Full Text] [Related]
17. Direct vascular effects of HMG-CoA reductase inhibitors.
Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
[TBL] [Abstract][Full Text] [Related]
18. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
Ahmadi Y; Ghorbanihaghjo A; Argani H
Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.
Jiang P; Mukthavaram R; Chao Y; Nomura N; Bharati IS; Fogal V; Pastorino S; Teng D; Cong X; Pingle SC; Kapoor S; Shetty K; Aggrawal A; Vali S; Abbasi T; Chien S; Kesari S
Br J Cancer; 2014 Oct; 111(8):1562-71. PubMed ID: 25093497
[TBL] [Abstract][Full Text] [Related]
20. Statins and protein prenylation in cancer cell biology and therapy.
Garcia-Ruiz C; Morales A; Fernandez-Checa JC
Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
